Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The company's Characterized Oral Desensitization ImmunoTherapy (CODIT?), is designed to desensitize patients to food allergens. The company's primary CODIT product candidate, AR101 is an investigational biologic for the treatment of patients with peanut allergy. The company is also exploring a product candidate designed to treat multi-nut allergy, including walnut allergy. The company is also conducting research and development activities for CODIT targeting other food allergies, including cow's milk allergy.
  • TickerAIMT
  • ISINUS00900T1079
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for AIMT

ValuEngine Rating and Forecast Report for AIMT

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for AIMT

ValuEngine Rating and Forecast Report for AIMT

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

1 director bought

A director at Aimmune Therapeutics Inc bought 12,500 shares at 22.337USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The na...

ValuEngine Rating and Forecast Report for AIMT

ValuEngine Rating and Forecast Report for AIMT

ValuEngine Rating and Forecast Report for AIMT

ValuEngine Rating and Forecast Report for AIMT

ValuEngine Rating and Forecast Report for AIMT

ValuEngine Rating and Forecast Report for AIMT

ValuEngine Rating and Forecast Report for AIMT

ValuEngine Rating and Forecast Report for AIMT

ValuEngine Rating and Forecast Report for AIMT

ValuEngine Rating and Forecast Report for AIMT

ResearchPool Subscriptions

Get the most out of your insights

Get in touch